109229
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
EGFR-TKI 治疗后出现获得性 EGFR T790M 突变的晚期非小细胞肺癌免疫治疗再挑战：一例报告
Authors Hu Y, Chen Z, Yao M, Gan L
Received 28 June 2025
Accepted for publication 19 October 2025
Published 7 November 2025 Volume 2025:17 Pages 2623—2629
DOI https://doi.org/10.2147/CMAR.S539675
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Sanjeev K. Srivastava
Yiqing Hu,1,2 Zhigang Chen,1 Mengxian Yao,1 Lei Gan1
1Department of Oncology, the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China; 2Clinical Medicine of Soochow University, the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China
Correspondence: Zhigang Chen, Department of Oncology, the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China, Tel +8613405093415, Email chenzhigung@foxmail.com
Abstract: Lung adenocarcinoma remains a leading cause of cancer mortality globally. While immune checkpoint inhibitors (ICIs) have improved outcomes in advanced non-small cell lung cancer (NSCLC), their efficacy in patients with acquired epidermal growth factor receptor (EGFR) T790M mutations following multiline therapy is poorly defined. This case report describes a 52-year-old Asian female never-smoker diagnosed with stage IIIA lung adenocarcinoma. She underwent lobectomy and received multiple lines of therapy. Initial genetic testing showed no EGFR T790M mutation, but subsequent testing after multiline treatment confirmed its acquired presence. Following multiline therapeutic failure, the patient received immunotherapy with cadonilimab (a PD-1/CTLA-4 bispecific antibody). This intervention resulted in disease control, and the patient achieved 9.4 months of progression free survival (PFS). This case suggests that immunotherapy with cadonilimab could be a potential consideration for advanced NSCLC harboring acquired EGFR T790M mutation post-multiline therapy.
Keywords: non-small cell lung cancer, cadonilimab, case report, immunotherapy, EGFR
1Department of Oncology, the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China; 2Clinical Medicine of Soochow University, the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China
Correspondence: Zhigang Chen, Department of Oncology, the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China, Tel +8613405093415, Email chenzhigung@foxmail.com
Abstract: Lung adenocarcinoma remains a leading cause of cancer mortality globally. While immune checkpoint inhibitors (ICIs) have improved outcomes in advanced non-small cell lung cancer (NSCLC), their efficacy in patients with acquired epidermal growth factor receptor (EGFR) T790M mutations following multiline therapy is poorly defined. This case report describes a 52-year-old Asian female never-smoker diagnosed with stage IIIA lung adenocarcinoma. She underwent lobectomy and received multiple lines of therapy. Initial genetic testing showed no EGFR T790M mutation, but subsequent testing after multiline treatment confirmed its acquired presence. Following multiline therapeutic failure, the patient received immunotherapy with cadonilimab (a PD-1/CTLA-4 bispecific antibody). This intervention resulted in disease control, and the patient achieved 9.4 months of progression free survival (PFS). This case suggests that immunotherapy with cadonilimab could be a potential consideration for advanced NSCLC harboring acquired EGFR T790M mutation post-multiline therapy.
Keywords: non-small cell lung cancer, cadonilimab, case report, immunotherapy, EGFR